BASF Se (BAS.SW)

Total Liabilities

€46.47B

Quarterly · Period ending: · EUR

BAS.SW logo

BAS.SW Total Liabilities

Latest reported€46.47B EUR
BAS.SW Quarterly Total Liabilities · EUR (€17.23B → €46.47B)
High-resolution chart · PNG

BAS.SW total liabilities history

Quarterly · EUR. Dates are reporting period ends; fiscal years can differ from calendar years.

BASF Se Total Liabilities — Quarterly (EUR)
Period endingTotal Liabilities (EUR)
46,471,000,000
46,345,788,000
43,680,755,000
42,567,000,000
44,164,000,000
44,068,000,000
43,532,000,000
43,314,000,000
45,726,000,000
43,184,000,000
40,750,000,000
42,333,000,000
44,176,000,000
44,080,000,000
46,135,961,000
47,930,000,000
50,599,000,000
51,428,000,000
47,973,652,000
45,488,000,000
44,857,000,000
45,799,000,000
45,894,000,000
52,341,000,000
51,988,000,000
48,985,000,000
44,600,000,000
48,215,000,000
47,912,000,000
54,225,000,000
50,447,000,000
48,938,000,000
46,556,000,000
44,066,000,000
44,012,000,000
42,682,000,000
43,209,000,000
44,510,000,000
43,928,000,000
43,366,000,000
43,191,000,000
42,827,000,000
39,291,000,000
42,237,000,000
45,113,000,000
49,081,000,000
43,164,000,000
42,864,000,000
41,533,000,000
39,554,000,000
36,593,000,000
38,505,000,000
38,274,000,000
39,063,000,000
38,523,000,000
38,486,000,000
39,514,000,000
37,820,000,000
35,790,000,000
35,986,000,000
36,300,000,000
36,687,000,000
36,736,000,000
34,609,000,000
36,625,000,000
34,388,000,000
32,659,000,000
34,390,000,000
32,138,000,000
29,683,000,000
28,941,000,000
27,714,000,000
26,704,200,000
25,773,000,000
27,531,002,820
26,388,985,680
26,712,880,725
27,749,587,320
26,901,875,000
19,928,116,550
18,132,824,559
20,000,093,780
21,302,386,560
19,880,522,530
18,137,192,837
19,128,225,480
18,632,503,680
18,755,839,280
17,692,265,200
19,595,009,700
19,774,859,830
19,853,603,000
18,160,008,832
18,360,538,460
18,897,908,400
19,913,686,100
19,386,893,412
21,016,564,200
19,969,255,200
21,885,796,600
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.